SG11201502887WA - Antibody-drug conjugate - Google Patents

Antibody-drug conjugate

Info

Publication number
SG11201502887WA
SG11201502887WA SG11201502887WA SG11201502887WA SG11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA
Authority
SG
Singapore
Prior art keywords
antibody
drug conjugate
conjugate
drug
Prior art date
Application number
SG11201502887WA
Other languages
English (en)
Inventor
Takeshi Masuda
Hiroyuki Naito
Takashi Nakada
Masao Yoshida
Shinji Ashida
Hideki Miyazaki
Yuji Kasuya
Koji Morita
Yuki Abe
Yusuke Ogitani
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502887W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201502887WA publication Critical patent/SG11201502887WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201502887WA 2012-10-11 2013-10-10 Antibody-drug conjugate SG11201502887WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012225887 2012-10-11
PCT/JP2013/006069 WO2014057687A1 (ja) 2012-10-11 2013-10-10 抗体－薬物コンジュゲート

Publications (1)

Publication Number Publication Date
SG11201502887WA true SG11201502887WA (en) 2015-05-28

Family

ID=50477169

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804788XA SG10201804788XA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate
SG11201502887WA SG11201502887WA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201804788XA SG10201804788XA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Country Status (30)

Country Link
US (6) US10195288B2 (enExample)
EP (3) EP3342785B1 (enExample)
JP (9) JP5953378B2 (enExample)
KR (15) KR102087017B1 (enExample)
CN (4) CN104755494B (enExample)
AU (5) AU2013328111B2 (enExample)
BR (3) BR122021014365B1 (enExample)
CA (2) CA3021435C (enExample)
CY (2) CY1120363T1 (enExample)
DK (2) DK3342785T3 (enExample)
ES (2) ES2773710T3 (enExample)
HR (2) HRP20180870T1 (enExample)
HU (2) HUE039000T2 (enExample)
IL (5) IL294622B2 (enExample)
LT (2) LT3342785T (enExample)
MX (3) MX364484B (enExample)
MY (1) MY170251A (enExample)
NZ (4) NZ705394A (enExample)
PH (2) PH12015500667B1 (enExample)
PL (2) PL2907824T3 (enExample)
PT (2) PT2907824T (enExample)
RS (2) RS57278B1 (enExample)
RU (1) RU2664465C2 (enExample)
SG (2) SG10201804788XA (enExample)
SI (2) SI2907824T1 (enExample)
SM (2) SMT201800344T1 (enExample)
TR (1) TR201809636T4 (enExample)
TW (14) TWI650312B (enExample)
WO (1) WO2014057687A1 (enExample)
ZA (2) ZA201501825B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963870A (zh) * 2016-06-08 2019-07-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
WO2021190602A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364484B (es) 2012-10-11 2019-04-29 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-fármaco.
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
HRP20250673T1 (hr) * 2013-12-25 2025-08-01 Daiichi Sankyo Company, Limited Postupak za proizvodnju konjugata anti-trop2 antitijelo-lijek
KR102314913B1 (ko) * 2014-01-31 2021-10-19 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
ES2754348T3 (es) * 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102186027B1 (ko) * 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2017110923A1 (ja) * 2015-12-24 2017-06-29 旭硝子株式会社 樹脂組成物、基材および細胞培養方法
CA3020864A1 (en) * 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3468993A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
TW201825524A (zh) * 2016-09-20 2018-07-16 中國大陸商上海藥明生物技術有限公司 新型抗-pcsk9抗體
KR20250040100A (ko) 2016-12-12 2025-03-21 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
TW202532106A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
TW201909926A (zh) * 2017-08-04 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
TWI880888B (zh) * 2017-08-23 2025-04-21 日商第一三共股份有限公司 抗體－藥物結合物之製劑及其冷凍乾燥方法
KR102816741B1 (ko) 2017-08-31 2025-06-04 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018342527B2 (en) 2017-09-29 2024-06-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
US20210283269A1 (en) 2018-07-25 2021-09-16 Daiichi Sankyo Company, Limited Effective method for manufacturing antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
CN112805036A (zh) 2018-07-31 2021-05-14 第一三共株式会社 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
CN112512587A (zh) 2018-08-06 2021-03-16 第一三共株式会社 抗体药物缀合物和微管蛋白抑制剂的组合
TW202016317A (zh) 2018-08-23 2020-05-01 日商第一三共股份有限公司 抗體藥物結合物之感受性標記
MX2021002107A (es) 2018-09-06 2021-04-28 Daiichi Sankyo Co Ltd Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo.
TW202024133A (zh) 2018-09-20 2020-07-01 日商第一三共股份有限公司 利用投予抗her3抗體-藥物結合物之her3突變癌之治療
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
US12377163B2 (en) * 2018-09-30 2025-08-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
BR112021009251A2 (pt) 2018-11-14 2021-08-10 Daiichi Sankyo Company, Limited conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
SG11202106248XA (en) * 2018-12-11 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate with parp inhibitor
CN113195000A (zh) * 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
BR112021018608A2 (pt) 2019-03-20 2021-11-23 Univ California Anticorpos para claudina-6 e conjugados de fármaco
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
PH12021552363A1 (en) * 2019-03-29 2022-09-05 Medimmune Ltd Compounds and conjugates thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
AU2020301289B2 (en) * 2019-06-28 2024-11-07 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof
CN112138171B (zh) * 2019-06-28 2024-09-24 泰州复旦张江药业有限公司 抗体偶联药物、其中间体、制备方法及应用
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
BR112022004913A2 (pt) * 2019-09-18 2022-06-07 Baili Bio Chengdu Pharmaceutical Co Ltd Derivado de camptotecina e conjugado do mesmo
KR20220113728A (ko) * 2019-12-12 2022-08-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 클라우딘 항체 약물 접합체 및 그 의약 용도
BR112022011632A2 (pt) * 2019-12-16 2022-10-04 Jiangsu Hengrui Medicine Co Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230101735A1 (en) 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
WO2021148003A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
TW202146055A (zh) 2020-02-25 2021-12-16 美商麥迪波士頓股份有限公司 喜樹鹼衍生物及其結合物
AU2021230226B2 (en) 2020-03-06 2025-06-26 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
CN115298220B (zh) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
EP4129345A4 (en) * 2020-03-25 2023-11-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF
JP2023519261A (ja) * 2020-03-25 2023-05-10 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｐｓｍａ抗体－エキサテカン類似体複合体及びその医薬用途
US20240261424A1 (en) * 2020-03-30 2024-08-08 National Cancer Center Antibody drug conjugate
CA3186295A1 (en) 2020-06-08 2021-12-16 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
EP4171654A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
TW202216208A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
IL299184A (en) 2020-07-06 2023-02-01 Byondis Bv Anti-folic acid drugs and antibody-conjugated drugs
EP4178559A4 (en) * 2020-07-10 2025-03-05 Velosbio Inc. Novel ror1 antibody immunoconjugates
BR112023000489A2 (pt) * 2020-07-13 2023-03-28 Regeneron Pharma Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
BR112023000711A2 (pt) 2020-07-17 2023-01-31 Daiichi Sankyo Co Ltd Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
CN119792568A (zh) 2020-08-13 2025-04-11 正大天晴药业集团股份有限公司 抗体药物偶联物
KR20230050378A (ko) 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
JPWO2022050300A1 (enExample) 2020-09-02 2022-03-10
CN116199739B (zh) 2020-09-30 2024-12-17 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
CA3195117A1 (en) 2020-10-09 2022-04-14 Jerome Thomas Mettetal Ii Combination of antibody-drug conjugate and parp1 selective inhibitor
JP2023545581A (ja) * 2020-10-12 2023-10-30 シーチュアン バイリ ファーム シーオー． エルティーディー カンプトテシン系誘導体及びそのリガンド－薬物複合体
US20230381332A1 (en) * 2020-10-12 2023-11-30 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof
TW202227140A (zh) 2020-11-11 2022-07-16 日商第一三共股份有限公司 抗體-藥物結合物及抗SIRPα抗體之組合
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
CN116615250A (zh) 2020-11-12 2023-08-18 第一三共株式会社 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗
JP7564958B2 (ja) * 2020-12-18 2024-10-09 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用
CA3202303C (en) * 2020-12-18 2024-06-25 Qingsong GUO Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
TW202241897A (zh) * 2020-12-23 2022-11-01 大陸商上海偌妥生物科技有限公司 抗體藥物結合物、醫藥組合物及治療應用
AU2022208361A1 (en) * 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Anti-dll3 antibody-drug conjugate
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
CN115279417B (zh) 2021-02-09 2025-01-03 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
US20240279364A1 (en) 2021-03-12 2024-08-22 Daiichi Sankyo Company, Limited Glycan, and method for producing medicine containing glycan
CN117015549A (zh) * 2021-03-17 2023-11-07 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
CN115197234A (zh) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 一种喜树碱衍生物中间体的制备方法
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
WO2022218331A1 (en) * 2021-04-14 2022-10-20 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
CN116917324A (zh) * 2021-04-26 2023-10-20 江苏恒瑞医药股份有限公司 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
CN113816969B (zh) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
AU2022294861B2 (en) * 2021-06-17 2025-09-11 Minghui Pharmaceutical (Hangzhou) Ltd. An anti-tumor compound and its application
US20240261426A1 (en) 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN113402584A (zh) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
IL309884A (en) * 2021-07-19 2024-03-01 Zeno Man Inc Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
US20240325564A1 (en) 2021-07-21 2024-10-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application
AU2022347380A1 (en) 2021-09-15 2024-04-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
EP4410830A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
CA3235358A1 (en) 2021-10-18 2023-04-27 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
KR20240101682A (ko) 2021-11-15 2024-07-02 시스트이뮨, 인코포레이티드 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022392822A1 (en) 2021-11-18 2024-05-02 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
AU2022401024A1 (en) 2021-11-30 2024-05-16 Daiichi Sankyo Company, Limited Protease-cleavable masked antibodies
KR20240112954A (ko) 2021-12-03 2024-07-19 시스트이뮨, 인코포레이티드 항-인간 trop2 항체-캄프토테신 약물 접합체 및 이의 의학적 용도
JP2025500952A (ja) 2021-12-23 2025-01-15 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｄｌｌ３抗体、その抗体－薬物複合体及びその医薬的使用
JP2024547111A (ja) * 2021-12-24 2024-12-26 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ＦＲα抗体及びその抗体薬物コンジュゲート並びに使用
IL313929A (en) 2021-12-28 2024-08-01 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and atr inhibitor
EP4456899A1 (en) 2021-12-28 2024-11-06 AstraZeneca UK Limited Combination of antibody-drug conjugate and rasg12c inhibitor
AU2022425491A1 (en) 2021-12-30 2024-07-04 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20250161473A1 (en) * 2022-01-18 2025-05-22 Gan & Lee Pharmaceuticals Co., Ltd. Exatecan derivative-antibody conjugate and medical use thereof
WO2023143263A1 (zh) 2022-01-25 2023-08-03 苏州宜联生物医药有限公司 一种针对Her3的抗体，偶联物及其用途
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
CN119095625A (zh) 2022-02-28 2024-12-06 Ｕｂｅ株式会社 抗体-药物偶联物
EP4487874A1 (en) 2022-02-28 2025-01-08 UBE Corporation Antibody-drug conjugate precursor and intermediate for synthesis thereof
JPWO2023167238A1 (enExample) 2022-03-02 2023-09-07
CA3245693A1 (en) 2022-03-10 2023-09-14 Vivasor, Inc. ANTIBODY-DRUG CONJUGATIONS AND THEIR USES
CA3255700A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited RATING METHOD FOR ANTI-TROP2 ANTIBODY-DRUG CONJUGATE THERAPY
US20250195681A1 (en) 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
IL316221A (en) 2022-04-12 2024-12-01 Minerva Biotechnologies Corp Anti-MUC1* variant antibodies and their uses
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
JP2025517656A (ja) 2022-05-11 2025-06-10 第一三共株式会社 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
KR20250012631A (ko) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 항-cdh6 항체-약물 접합체의 투약
CN119677542A (zh) 2022-06-03 2025-03-21 Ｕｂｅ株式会社 抗体-多药物缀合物前体及其合成中间体
CN119630430A (zh) 2022-06-03 2025-03-14 Ｕｂｅ株式会社 抗体多药物缀合物
CN119384296A (zh) 2022-06-07 2025-01-28 映恩生物制药（苏州）有限公司 抗b7h3抗体-药物偶联物及其用途
WO2023237050A1 (en) * 2022-06-09 2023-12-14 Beigene, Ltd. Antibody drug conjugates
US20250367311A1 (en) 2022-06-15 2025-12-04 Shanghai Hansoh Biomedical Co., Ltd. Pharmaceutical composition containing an antibody-drug conjugate and use thereof
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
CN118955615A (zh) * 2022-07-05 2024-11-15 上海药明合联生物技术有限公司 偶联连接子
AU2023306832A1 (en) 2022-07-11 2025-02-13 Pinotbio, Inc. Ddx5 protein-binding camptothecin derivatives and prodrugs thereof
CA3261857A1 (en) 2022-07-14 2025-06-28 Medilink Therapeutics (Suzhou) Co., Ltd. ANTIBODY-DRUG CONJUGATE, ITS PREPARATION PROCESS AND ITS USE
AR129935A1 (es) 2022-07-15 2024-10-16 Genequantum Healthcare Suzhou Co Ltd Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos
CA3262616A1 (en) * 2022-07-22 2024-01-25 Nj Bio, Inc. HEXACYCLIC TOPOISOMERASE INHIBITORS WITH CYTOTOXIC ACTIVITY ON CANCER CELLS
KR20250049293A (ko) 2022-07-27 2025-04-11 밍훼이 파마슈티컬 (항저우) 리미티드 항체-약물 접합체 및 이의 용도
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
MA71616A (fr) 2022-07-28 2025-05-30 Daiichi Sankyo Company, Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
TW202415409A (zh) 2022-08-02 2024-04-16 中國商諾納生物（蘇州）有限公司 Msln抗體藥物複合體
JP2025531032A (ja) 2022-08-25 2025-09-19 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． 抗体薬物複合体の医薬組成物
AU2023336004A1 (en) 2022-08-29 2025-03-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
JP2025511436A (ja) * 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
EP4585601A1 (en) 2022-09-09 2025-07-16 Daiichi Sankyo Company, Limited Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN120265285A (zh) * 2022-09-26 2025-07-04 索尔夫治疗公司 组合物及其用途
EP4594327A1 (en) * 2022-09-30 2025-08-06 BeiGene Switzerland GmbH Ligand-drug conjugate of exatecan analogue, and medical use thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
AU2023359114A1 (en) 2022-10-09 2025-04-24 LaNova Medicines Limited Compounds, compositions and methods
JP2025523332A (ja) 2022-10-25 2025-07-23 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来ａｄｃリンカー－ペイロード、医薬組成物、及びそれの使用
EP4622677A1 (en) 2022-11-24 2025-10-01 BeiGene Switzerland GmbH Anti-cea antibody drug conjugates and methods of use
CN120265326A (zh) * 2022-11-25 2025-07-04 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用
CN118105508A (zh) * 2022-11-29 2024-05-31 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
TW202440169A (zh) 2022-11-30 2024-10-16 日商第一三共股份有限公司 抗體-藥物結合物與dnmt抑制劑之組合
CN116621927B (zh) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
AR131815A1 (es) 2023-02-09 2025-05-07 Beigene Ltd Conjugados de enlace autoestabilizantes
AU2024228867A1 (en) * 2023-02-27 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof
TW202444423A (zh) 2023-03-14 2024-11-16 日商第一三共股份有限公司 抗cdh6抗體-藥物結合物與vegf抑制劑之組合
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
WO2024194851A1 (en) * 2023-03-23 2024-09-26 Beigene Switzerland Gmbh Bioactive conjugate, preparation method therefor and use thereof
CN120917143A (zh) 2023-03-29 2025-11-07 第一三共株式会社 抗cd25抗体及抗cd25抗体-药物偶联物
KR20250173601A (ko) 2023-03-31 2025-12-10 다이이찌 산쿄 가부시키가이샤 항 CDH6 항체-약물 콘주게이트와 HIF-2α 저해제의 조합
AU2024243661A1 (en) 2023-04-04 2025-11-06 Ajinomoto Co., Inc. Antibody-functional substance conjugate, antibody derivative, and compound, or salts thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024210178A1 (ja) 2023-04-05 2024-10-10 味の素株式会社 抗体および機能性物質のコンジュゲートまたはその塩、ならびにチオール基を有する抗体中間体またはその塩
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
CN121127269A (zh) 2023-04-13 2025-12-12 启德医药科技（苏州）有限公司 抗体-药物偶联物和抗pd-1抗体的组合及其用途
AU2024270034A1 (en) 2023-05-06 2025-12-04 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Deuterated camptothecin compound, and preparation therefor and use thereof
WO2024230752A1 (zh) 2023-05-08 2024-11-14 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof
WO2024235274A1 (zh) * 2023-05-16 2024-11-21 石药集团巨石生物制药有限公司 一种抗体药物偶联物的药物组合物
CN119546347A (zh) * 2023-06-29 2025-02-28 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
WO2025036480A1 (zh) * 2023-08-16 2025-02-20 中山康方生物医药有限公司 化合物以及含有该化合物的抗体偶联药物
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
US20250222125A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2025185559A1 (zh) * 2024-03-04 2025-09-12 杭州中美华东制药有限公司 抗FGFR2b抗体、其抗体药物偶联物及其用途
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗b7-h4抗体药物偶联物及其应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JPH0559061U (ja) 1991-04-18 1993-08-03 株式会社ケイヴイシー ボールバルブ
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (ja) 1993-06-02 1994-12-22 株式会社ユニシアジェックス 液圧緩衝器のリザーバチューブ構造
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JPH08337584A (ja) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd 縮合六環式アミノ化合物、これを含有する医薬及びその製法
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH1095802A (ja) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
JPH1171280A (ja) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
JPH1192405A (ja) * 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd 薬物複合体
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AU3733399A (en) * 1998-05-22 1999-12-13 Daiichi Pharmaceutical Co., Ltd. Drug composites
CN1191093C (zh) 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むｄｄｓ化合物
KR20030031502A (ko) 2000-06-29 2003-04-21 다이이찌 세이야꾸 가부시기가이샤 디디에스 화합물 및 그의 제조방법
US6815435B2 (en) 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
BRPI0508233A (pt) 2004-02-26 2007-07-17 Inotek Pharmaceuticals Corp derivados de isoquinolina e métodos para emprego destes
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
MXPA06013413A (es) * 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP1817341A2 (en) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DE102005009084A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
DE102005009099A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
CN101490087B (zh) 2006-05-30 2013-11-06 健泰科生物技术公司 抗体和免疫偶联物及其用途
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
JPWO2007145306A1 (ja) * 2006-06-15 2009-11-12 国立大学法人 北海道大学 腫瘍組織で選択的に分解性を示す血中滞留性素子
ITMI20061473A1 (it) 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
MX2009006885A (es) 2006-12-21 2009-08-28 Schering Corp Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
KR20100014527A (ko) * 2007-03-22 2010-02-10 슬로안-케테링인스티튜트퍼캔서리서치 단일클론항체 8ｈ9의 용도
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
WO2010089782A1 (en) 2009-02-05 2010-08-12 Saverio Alberti Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
WO2011021397A1 (ja) 2009-08-20 2011-02-24 国立大学法人千葉大学 コルヒチン誘導体
JP2013505944A (ja) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
PH12013500070A1 (en) 2010-07-12 2017-08-23 Covx Tech Ireland Ltd Multifunctional antibody conjugates
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
EP2861259A1 (en) 2012-06-14 2015-04-22 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
MX364484B (es) * 2012-10-11 2019-04-29 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-fármaco.
ES2782248T3 (es) * 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
JP6262768B2 (ja) 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
CN103313390B (zh) 2013-07-05 2016-01-20 江苏大学 一种基于双移动信标的wsn定位方法
KR102314913B1 (ko) * 2014-01-31 2021-10-19 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102199434B1 (ko) 2017-02-24 2021-01-06 장길훈 대화형 애플리케이션의 메시지 공유 시스템과 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963870A (zh) * 2016-06-08 2019-07-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
WO2021190602A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法

Also Published As

Publication number Publication date
MX2015003903A (es) 2015-07-17
TWI877063B (zh) 2025-03-11
AU2022203560B2 (en) 2025-02-06
KR102417310B1 (ko) 2022-07-05
JP2024147681A (ja) 2024-10-16
KR20200026323A (ko) 2020-03-10
SI2907824T1 (en) 2018-06-29
CN113929738B (zh) 2024-05-17
SI3342785T1 (sl) 2020-02-28
TWI870274B (zh) 2025-01-11
CA3021435C (en) 2021-10-12
KR102369419B1 (ko) 2022-03-02
US20150297748A1 (en) 2015-10-22
CN104755494B (zh) 2018-09-07
ES2773710T3 (es) 2020-07-14
MY170251A (en) 2019-07-13
TWI615152B (zh) 2018-02-21
KR20230142808A (ko) 2023-10-11
KR20240144454A (ko) 2024-10-02
JP6715888B2 (ja) 2020-07-01
KR102584005B1 (ko) 2023-09-27
KR20190135559A (ko) 2019-12-06
EP2907824A1 (en) 2015-08-19
KR101841818B1 (ko) 2018-03-26
BR122021014365B1 (pt) 2022-07-05
JP2020180124A (ja) 2020-11-05
TW202444429A (zh) 2024-11-16
RS57278B1 (sr) 2018-08-31
TW202444428A (zh) 2024-11-16
TWI870275B (zh) 2025-01-11
JP2016196484A (ja) 2016-11-24
US10195288B2 (en) 2019-02-05
TWI757740B (zh) 2022-03-11
CA2885800C (en) 2018-12-04
NZ705394A (en) 2018-10-26
TWI870276B (zh) 2025-01-11
DK3342785T3 (da) 2020-03-23
KR20210038728A (ko) 2021-04-07
CA2885800A1 (en) 2014-04-17
CN113929738A (zh) 2022-01-14
NZ746440A (en) 2019-11-29
AU2022203560A1 (en) 2022-06-16
RU2018128384A3 (enExample) 2021-12-20
TW201420117A (zh) 2014-06-01
IL238143B (en) 2020-01-30
US20190008981A1 (en) 2019-01-10
JP6186045B2 (ja) 2017-08-23
IL271760A (en) 2020-02-27
IL294622B1 (en) 2023-06-01
TW202033499A (zh) 2020-09-16
TWI650312B (zh) 2019-02-11
HRP20200353T1 (hr) 2020-06-12
TR201809636T4 (tr) 2018-07-23
TW201920098A (zh) 2019-06-01
JPWO2014057687A1 (ja) 2016-09-05
KR102320907B1 (ko) 2021-11-02
TW202448521A (zh) 2024-12-16
JP2018188455A (ja) 2018-11-29
IL313147A (en) 2024-07-01
EP2907824B1 (en) 2018-04-11
HK1210477A1 (en) 2016-04-22
JP2018008982A (ja) 2018-01-18
BR122021014396B1 (pt) 2022-07-05
AU2025202668A1 (en) 2025-07-03
RS60000B1 (sr) 2020-04-30
KR102498405B1 (ko) 2023-02-09
CN115960111A (zh) 2023-04-14
TWI870273B (zh) 2025-01-11
AU2013328111B2 (en) 2017-11-02
KR102052319B1 (ko) 2019-12-05
NZ740948A (en) 2019-11-29
HUE039000T2 (hu) 2018-12-28
KR20150067149A (ko) 2015-06-17
RU2018128384A (ru) 2018-10-02
DK2907824T3 (en) 2018-07-23
CN109081871B (zh) 2023-07-14
TW202444367A (zh) 2024-11-16
JP7170812B2 (ja) 2022-11-14
IL302494A (en) 2023-06-01
TWI877062B (zh) 2025-03-11
US20240082413A1 (en) 2024-03-14
CN109081871A (zh) 2018-12-25
IL271760B (en) 2022-08-01
KR102087017B1 (ko) 2020-03-10
TW201811746A (zh) 2018-04-01
US20200282073A1 (en) 2020-09-10
US20160279259A1 (en) 2016-09-29
KR20210132240A (ko) 2021-11-03
PH12015500667A1 (en) 2015-05-18
AU2013328111A1 (en) 2015-03-12
ZA201501825B (en) 2022-05-25
ES2671644T3 (es) 2018-06-07
KR20220100727A (ko) 2022-07-15
KR20220146669A (ko) 2022-11-01
AU2020200548A1 (en) 2020-02-13
KR102456726B1 (ko) 2022-10-20
PT2907824T (pt) 2018-06-07
TW202448522A (zh) 2024-12-16
ZA201900820B (en) 2022-08-31
US20250049782A1 (en) 2025-02-13
TWI879657B (zh) 2025-04-01
JP6952835B2 (ja) 2021-10-27
AU2018200308A1 (en) 2018-02-01
KR20220029776A (ko) 2022-03-08
LT2907824T (lt) 2018-06-11
KR20230024433A (ko) 2023-02-20
TWI879656B (zh) 2025-04-01
RU2664465C2 (ru) 2018-08-17
PH12015500667B1 (en) 2019-03-06
IL302494B1 (en) 2024-07-01
JP2023011799A (ja) 2023-01-24
KR102853456B1 (ko) 2025-09-01
TW202448523A (zh) 2024-12-16
TW202233186A (zh) 2022-09-01
HK1256631A1 (en) 2019-09-27
SMT202000138T1 (it) 2020-05-08
PL2907824T3 (pl) 2018-08-31
TW202444366A (zh) 2024-11-16
SG10201804788XA (en) 2018-07-30
TW202448463A (zh) 2024-12-16
PH12018501433A1 (en) 2019-02-27
KR20250130442A (ko) 2025-09-01
JP6371452B2 (ja) 2018-08-08
KR101901558B1 (ko) 2018-09-21
RU2015113767A (ru) 2016-12-10
LT3342785T (lt) 2020-02-10
KR102540419B1 (ko) 2023-06-05
SMT201800344T1 (it) 2018-09-13
TWI696611B (zh) 2020-06-21
KR102709509B1 (ko) 2024-09-24
EP2907824A4 (en) 2016-06-08
BR112015006521B1 (pt) 2022-03-03
IL294622A (en) 2022-09-01
AU2020200548B2 (en) 2022-08-25
US9808537B2 (en) 2017-11-07
KR20180030734A (ko) 2018-03-23
JP5953378B2 (ja) 2016-07-20
US11633493B2 (en) 2023-04-25
TWI879658B (zh) 2025-04-01
EP3342785B1 (en) 2019-12-25
CA3021435A1 (en) 2014-04-17
WO2014057687A1 (ja) 2014-04-17
JP2017036274A (ja) 2017-02-16
EP3632471A1 (en) 2020-04-08
IL294622B2 (en) 2023-10-01
US12186310B2 (en) 2025-01-07
TW202448464A (zh) 2024-12-16
KR20180105271A (ko) 2018-09-27
IL238143A0 (en) 2015-05-31
NZ746439A (en) 2019-11-29
TW202448462A (zh) 2024-12-16
JP6030267B1 (ja) 2016-11-24
HUE048748T2 (hu) 2020-08-28
BR112015006521A2 (enExample) 2017-09-05
US10973924B2 (en) 2021-04-13
TWI879659B (zh) 2025-04-01
CY1122789T1 (el) 2021-05-05
EP3342785A1 (en) 2018-07-04
KR102237639B1 (ko) 2021-04-07
MX2020010964A (es) 2020-11-09
CN104755494A (zh) 2015-07-01
KR20230086800A (ko) 2023-06-15
CY1120363T1 (el) 2019-07-10
AU2018200308B2 (en) 2019-11-07
MX364484B (es) 2019-04-29
IL302494B2 (en) 2024-11-01
PL3342785T3 (pl) 2020-09-07
JP2022008581A (ja) 2022-01-13
PT3342785T (pt) 2020-02-25
JP7523506B2 (ja) 2024-07-26
HRP20180870T1 (hr) 2018-07-13
MX2019004502A (es) 2019-08-21

Similar Documents

Publication Publication Date Title
HUS2500038I1 (hu) Anti-trop2 antitest-gyógyszer konjugátum
ZA201900820B (en) Antibody-drug conjugate
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
SG10201605401WA (en) Antibody-drug conjugates
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
HUE037604T2 (hu) Hatóanyag-protein konjugátumok
IL237672A0 (en) Drug-protein conjugates
IL234604A (en) Carbon-glycophide vaccines are vaccinated
ZA201409119B (en) Polymer-nsaid conjugate
GB2508089B (en) Underpants